nach oben

International Urology and Nephrology

Erschienen in:

20.09.2019 | Urology - Original Paper

The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results

verfasst von: Ismail Selvi, Umut Demirci, Nazan Bozdogan, Halil Basar

Erschienen in: International Urology and Nephrology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aimed to evaluate the density of CD8⁺ and CD3⁺ tumor-infiltrating lymphocytes (TILs) and determine whether the immunoscore has any prognostic effect on the oncological outcomes in patients with clear cell renal cell carcinoma (RCC).

Materials and methods

A total of 129 patients diagnosed with clear cell RCC following radical or partial nephrectomy between 2009 and 2014 were retrospectively analyzed. Both tumor core (CT) and the invasive margin of nephrectomy specimens were assessed. The specimens were immunostained for anti-CD8⁺ and anti-CD3⁺ TILs. The patients were divided into three groups (favorable, intermediate, and poor risk) according to immunoscore levels.

Results

In the multivariate analysis, a favorable immunoscore (I3–4) was associated with prolonged disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) (HR 2.652, 2.848, and 2.933, respectively; all p < 0.001). The lower Fuhrman grade and pathological tumor-node-metastasis (TNM) stage had better DFS, PFS, and OS, whereas prolonged PFS was associated with a higher density of CD8⁺ CT (HR 1.602, 95% CI 0.934–3.470; p = 0.014). The shorter DFS, PFS, and OS were observed in the group with poor immunoscore (I0–1) at the early TNM stage of RCC (p < 0.001). In the metastatic subgroup analysis, the immunoscore showed better estimation than the International Metastatic RCC Database Consortium model and the Memorial Sloan-Kettering Cancer Center risk model for progression and OS (p < 0.001).

Conclusion

The additional contributions of immunoscore to TNM stage, Fuhrman grade, and the WHO/ISUP 2016 grade for estimating oncological outcomes were found in ROC analysis. According to our preliminary results, immunoscore can be a promising prediction tool in clear cell RCC for postoperative oncological outcomes following nephrectomy.

Rendon RA, Kapoor A, Breau R et al (2014) Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J 8:398–412CrossRef

Lipworth L, Tarone RE, McLaughlin JK (2006) The epidemiology of renal cell carcinoma. J Urol 176:2353–2358CrossRef

Ljungberg B, Albiges L, Bensalah K et al (2019) European Association of Urology guidelines on renal cell carcinoma: the 2019 update. In. ISBN 978-94-92671-04-2. EAU Guidelines Office, Arnhem, The Netherlands. ISBN 978-94-92671-04-2. http://uroweb.org/guidelines/compilations-of-all-guidelines/. Accessed 19 Mar 2019

Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA et al (2012) The immune score as a new possible approach for the classification of cancer. J Transl Med 10:1–4CrossRef

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C et al (2014) Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 232:199–209CrossRef

Kim JK, Kim SH, Song MK, Joo J, Seo SI, Kwak C et al (2019) Application of the international metastatic renal cell carcinoma database consortium and memorial Sloan Kettering cancer center risk models in patients with metastatic non-clear cell renal cell carcinoma: a multi-institutional retrospective study using the korean metastatic renal cell carcinoma registry. Cancer Res Treat 51(2):758–768CrossRef

Bindea G, Mlecnik B, Angell HK, Galon J (2014) The immune landscape of human tumors implications for cancer immunotherapy. OncoImmunology 3:27456–27458CrossRef

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D et al (2016) Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3):698–711CrossRef

Kirilovsky A, Marliot F, Sissy CE, Haicheur N, Galon J, Pagès F (2016) Rational bases for the use of the immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol 28:216–226CrossRef

10.

Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T et al (2018) Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx123 CrossRefPubMed

11.

Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM et al (2014) Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 20(7):1891–1899CrossRef

12.

Rabjerg M (2017) Identification and validation of novel prognostic markers in renal cell carcinoma. Dan Med J 64(10):B5339PubMed

13.

Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306CrossRef

14.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674CrossRef

15.

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G (2017) The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 14(12):717–734CrossRef

16.

Ingels A, Salas RES, Ravery V, Fromont-Hankard G, Validire P, Patard JJ et al (2014) T-helper 1 immunoreaction influences survival in muscle-invasive bladder cancer: proof of concept. Ecancer Med Sci 8:486

17.

Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S et al (2007) CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 104:3967–3972CrossRef

18.

Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A et al (2013) The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. Journal of Translational Medicine 11:54–57CrossRef

19.

Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT et al (2018) Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3⁺ , CD8⁺ , and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One 13(10):e0205746. https://doi.org/10.1371/journal.pone.0205746.eCollection2018 CrossRefPubMedPubMedCentral

20.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A et al (2012) Cancer classification using the immunoscore: a worldwide task force. J Transl Med 10:205–213CrossRef

21.

Sun C, Xu J, Song J, Liu CQ, Wang J, Weng C et al (2015) The predictive value of centre tumour CD8⁺ T cells in patients with hepatocellular carcinoma: comparison with immunoscore. Oncotarget 34:35602–35615

22.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T et al (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29:610–618CrossRef

23.

Faraj S, Munari E, Guner G, Taube J, Anders R, Hicks J et al (2015) Assessment of tumoral PD-L1 expression and intratumoral CD8⁺ T cells in urothelial carcinoma. Urology 85:703–708CrossRef

24.

Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P et al (2016) The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol 34:181–187CrossRef

25.

Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L et al (2015) Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 6:24990–25002CrossRef

26.

Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M et al (2015) Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 6(38):40836–40849CrossRef

27.

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER). NCT03055013. https://clinicaltrials.gov/ct2/home. Accessed 24 May 2017

28.

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010). NCT03024996 Available at:https://clinicaltrials.gov/ct2/home. Accessed 24 May 2017

29.

Zahoor H, Pavicic PG Jr, Przybycin C, Ko J, Stephens L, Radivoyevitch T et al (2018) Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. Medicine (Baltimore) 97(37):e12344CrossRef

Titel: The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results
verfasst von: Ismail Selvi
Umut Demirci
Nazan Bozdogan
Halil Basar
Publikationsdatum: 20.09.2019
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2020
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-019-02285-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients

HPV infection in urology practice

Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria

The epidemiology and role of surgery in the treatment of urethral clear cell carcinoma

Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis